Buys | $0 | 0 | 0 |
Sells | $1,529,038 | 25 | 100 |
Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 0 | $0 | 1 | $3,866 | $-3,866 |
Mason Michael | EVP, CFO & Treasurer | 0 | $0 | 2 | $5,734 | $-5,734 |
Poulton Stuart | EVP, Chief Development Officer | 0 | $0 | 2 | $6,782 | $-6,782 |
Rangwala Reshma | EVP & Chief Medical Officer | 0 | $0 | 1 | $7,943 | $-7,943 |
Mano Michael | SVP, General Counsel&Secretary | 0 | $0 | 2 | $20,434 | $-20,434 |
Paulson Richard A. | President and CEO | 0 | $0 | 11 | $36,562 | $-36,562 |
PAKIANATHAN DEEPIKA | director | 0 | $0 | 6 | $1.45M | $-1.45M |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with …
Over the last 12 months, insiders at Karyopharm Therapeutics Inc. have bought $0 and sold $1.53M worth of Karyopharm Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Karyopharm Therapeutics Inc. have bought $130,090 and sold $2.6M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,140 shares for transaction amount of $49,985 was made by BOHLIN GAREN G (director) on 2023‑09‑12.
2025-03-04 | Sale | Mano Michael | SVP, General Counsel&Secretary | 2,793 0.0333% | $6.29 | $17,568 | +8.24% | |
2025-02-18 | Sale | Poulton Stuart | EVP, Chief Development Officer | 5,914 0.0048% | $0.63 | $3,726 | -19.52% | |
2025-02-04 | Sale | Paulson Richard A. | President and CEO | 4,099 0.0034% | $0.65 | $2,664 | -5.48% | |
2025-01-06 | Sale | Paulson Richard A. | President and CEO | 4,055 0.0031% | $0.78 | $3,175 | -25.00% | |
2024-12-04 | Sale | Paulson Richard A. | President and CEO | 3,620 0.003% | $0.81 | $2,932 | -18.29% | |
2024-11-05 | Sale | Paulson Richard A. | President and CEO | 3,675 0.0029% | $0.91 | $3,346 | -20.57% | |
2024-10-04 | Sale | Paulson Richard A. | President and CEO | 3,607 0.0036% | $0.88 | $3,172 | -20.96% | |
2024-09-04 | Sale | Paulson Richard A. | President and CEO | 3,667 0.003% | $0.72 | $2,647 | +2.43% | |
2024-09-04 | Sale | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | 5,356 0.0044% | $0.72 | $3,866 | +2.43% | |
2024-09-04 | Sale | Mason Michael | EVP, CFO & Treasurer | 7,050 0.0057% | $0.72 | $5,089 | +2.43% | |
2024-09-04 | Sale | Mano Michael | SVP, General Counsel&Secretary | 3,971 0.0032% | $0.72 | $2,866 | +2.43% | |
2024-08-06 | Sale | Paulson Richard A. | President and CEO | 3,608 0.0032% | $0.93 | $3,355 | -10.71% | |
2024-07-30 | Sale | Poulton Stuart | EVP, Chief Development Officer | 2,883 0.0023% | $1.06 | $3,056 | -28.11% | |
2024-07-05 | Sale | Paulson Richard A. | President and CEO | 3,616 0.0025% | $0.85 | $3,077 | -5.05% | |
2024-06-07 | Sale | PAKIANATHAN DEEPIKA | director | 2,240 0.0018% | $0.95 | $2,130 | -16.88% | |
2024-06-06 | Sale | PAKIANATHAN DEEPIKA | director | 118,452 0.096% | $0.98 | $116,415 | -17.85% | |
2024-06-05 | Sale | PAKIANATHAN DEEPIKA | director | 468,044 0.3619% | $0.96 | $448,480 | -19.57% | |
2024-06-04 | Sale | Paulson Richard A. | President and CEO | 3,592 0.0033% | $0.99 | $3,556 | -13.73% | |
2024-06-04 | Sale | Mason Michael | EVP, CFO & Treasurer | 652 0.0006% | $0.99 | $645 | -13.73% | |
2024-06-04 | Sale | PAKIANATHAN DEEPIKA | director | 341,040 0.2976% | $0.95 | $324,704 | -13.73% |
PAKIANATHAN DEEPIKA | director | 0 0% | $0 | 5 | 7 | +36.66% |
Frenkel Ran | EVP, Chief Dev. Officer | 168290 1.9996% | $1.14M | 2 | 9 | <0.0001% |
Shah Jatin | EVP, Chief Medical Officer | 129450 1.5381% | $873,787.50 | 1 | 6 | <0.0001% |
Brannelly Paul | SVP, FINANCE & ADMIN, TREAS | 66136 0.7858% | $446,418.00 | 3 | 0 | +28.23% |
BOHLIN GAREN G | director | 45140 0.5364% | $304,695.00 | 2 | 0 | <0.0001% |
$6,787,959 | 35 | 49.84% | $60.62M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$144,247,213 | 29 | 10.15% | $64.24M | |
$2,239,226 | 28 | 3.41% | $63.36M | |
$26,736,140 | 20 | -18.64% | $54.85M |
Increased Positions | 34 | +28.81% | 681,637 | +17.18% |
Decreased Positions | 44 | -37.29% | 587,793 | -14.82% |
New Positions | 14 | New | 191,230 | New |
Sold Out Positions | 21 | Sold Out | 122,214 | Sold Out |
Total Postitions | 108 | -8.47% | 4M | +2.37% |
Vanguard Group Inc | $4,057.00 | 6.38% | 510,324 | 0 | 0% | 2024-12-31 |
Adage Capital Partners Gp, L.L.C. | $3,350.00 | 5.27% | 421,344 | +133,340 | +46.3% | 2024-12-31 |
Palo Alto Investors Lp | $2,601.00 | 4.09% | 327,150 | -13,013 | -3.83% | 2024-12-31 |
Blackrock, Inc. | $1,998.00 | 3.14% | 251,271 | +8,700 | +3.59% | 2024-12-31 |
Morgan Stanley | $1,862.00 | 2.93% | 234,224 | +225,980 | +2,741.14% | 2024-12-31 |
Citadel Advisors Llc | $1,645.00 | 2.59% | 206,922 | 0 | 0% | 2024-12-31 |
Marshall Wace, Llp | $1,273.00 | 2% | 160,102 | +21,280 | +15.33% | 2024-12-31 |
Catalio Capital Management, Lp | $1,237.00 | 1.95% | 155,633 | +155,633 | New | 2024-12-31 |
Eversept Partners, Lp | $1,107.00 | 1.74% | 139,257 | -230,620 | -62.35% | 2024-12-31 |
Avidity Partners Management Lp | $1,070.00 | 1.68% | 134,573 | 0 | 0% | 2024-12-31 |